Kura Oncology Inc

KURA remains in a constructive medium- and long-term uptrend but is undergoing a short-term pullback toward the 50-day SMA. No oversold or exhaustion signals are present, so new exposure is best deferred until price accepts support at the 50-day SMA and confirms resumed upside momentum.

• ↑Q2 2026 revenue $20.9M (+36% YoY); KOMZIFTI sales $9.1M (+57% QoQ)
• ↑$519M in cash/short-term investments funds operations to 2028 Phase 3 readout
• ↓Q2 net loss $68.3M; trailing 12-month net loss ~$296.8M